These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 18535402)
1. Inhibition of MDM2-p53 feedback loop by various small molecules for potential cancer chemotherapy. Khan A; Lu H Cancer Biol Ther; 2008 Jun; 7(6):853-5. PubMed ID: 18535402 [No Abstract] [Full Text] [Related]
2. A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis and sensitizes lung cancer cells to chemotherapy. Sun SH; Zheng M; Ding K; Wang S; Sun Y Cancer Biol Ther; 2008 Jun; 7(6):845-52. PubMed ID: 18340116 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53. Tian X; Dai S; Sun J; Jiang S; Sui C; Meng F; Li Y; Fu L; Jiang T; Wang Y; Su J; Jiang Y Cell Physiol Biochem; 2016; 39(5):2088-2098. PubMed ID: 27825169 [TBL] [Abstract][Full Text] [Related]
4. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. Yu S; Qin D; Shangary S; Chen J; Wang G; Ding K; McEachern D; Qiu S; Nikolovska-Coleska Z; Miller R; Kang S; Yang D; Wang S J Med Chem; 2009 Dec; 52(24):7970-3. PubMed ID: 19928922 [TBL] [Abstract][Full Text] [Related]
5. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function. Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313 [TBL] [Abstract][Full Text] [Related]
6. Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells. Chen H; Luo D; Zhang L; Lin X; Luo Q; Yi H; Wang J; Yan X; Li B; Chen Y; Liu X; Zhang H; Liu S; Qiu M; Yang D; Jiang N Oncotarget; 2017 Jun; 8(26):43008-43022. PubMed ID: 28498808 [TBL] [Abstract][Full Text] [Related]
7. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Azmi AS; Aboukameel A; Banerjee S; Wang Z; Mohammad M; Wu J; Wang S; Yang D; Philip PA; Sarkar FH; Mohammad RM Eur J Cancer; 2010 Apr; 46(6):1122-31. PubMed ID: 20156675 [TBL] [Abstract][Full Text] [Related]
8. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Shangary S; Qin D; McEachern D; Liu M; Miller RS; Qiu S; Nikolovska-Coleska Z; Ding K; Wang G; Chen J; Bernard D; Zhang J; Lu Y; Gu Q; Shah RB; Pienta KJ; Ling X; Kang S; Guo M; Sun Y; Yang D; Wang S Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3933-8. PubMed ID: 18316739 [TBL] [Abstract][Full Text] [Related]
9. Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges. Wang S; Zhao Y; Aguilar A; Bernard D; Yang CY Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28270530 [TBL] [Abstract][Full Text] [Related]
10. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma. Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran-oxindole derivatives as potent p53-MDM2 inhibitors. Ji C; Wang S; Chen S; He S; Jiang Y; Miao Z; Li J; Sheng C Bioorg Med Chem; 2017 Oct; 25(20):5268-5277. PubMed ID: 28797774 [TBL] [Abstract][Full Text] [Related]
12. Targeted Degradation of MDM2 as a New Approach to Improve the Efficacy of MDM2-p53 Inhibitors. Wurz RP; Cee VJ J Med Chem; 2019 Jan; 62(2):445-447. PubMed ID: 30575392 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, Biological and In Silico Evaluation of Pure Nucleobase-Containing Spiro (Indane-Isoxazolidine) Derivatives as Potential Inhibitors of MDM2-p53 Interaction. Maiuolo L; Algieri V; Russo B; Tallarida MA; Nardi M; Di Gioia ML; Merchant Z; Merino P; Delso I; De Nino A Molecules; 2019 Aug; 24(16):. PubMed ID: 31405162 [TBL] [Abstract][Full Text] [Related]
14. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner. Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384 [TBL] [Abstract][Full Text] [Related]
15. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy. Gupta AK; Bharadwaj M; Kumar A; Mehrotra R Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171 [TBL] [Abstract][Full Text] [Related]
16. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways. Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175 [TBL] [Abstract][Full Text] [Related]
17. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mohammad RM; Wu J; Azmi AS; Aboukameel A; Sosin A; Wu S; Yang D; Wang S; Al-Katib AM Mol Cancer; 2009 Dec; 8():115. PubMed ID: 19958544 [TBL] [Abstract][Full Text] [Related]
18. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313 [TBL] [Abstract][Full Text] [Related]
19. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. Zhao Y; Yu S; Sun W; Liu L; Lu J; McEachern D; Shargary S; Bernard D; Li X; Zhao T; Zou P; Sun D; Wang S J Med Chem; 2013 Jul; 56(13):5553-61. PubMed ID: 23786219 [TBL] [Abstract][Full Text] [Related]
20. Synthesis of spiro-tetrahydrothiopyran-oxindoles by Michael-aldol cascade reactions: discovery of potential P53-MDM2 inhibitors with good antitumor activity. Wang S; Chen S; Guo Z; He S; Zhang F; Liu X; Chen W; Zhang S; Sheng C Org Biomol Chem; 2018 Jan; 16(4):625-634. PubMed ID: 29302672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]